Cargando…

Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study

BACKGROUND: In patients with cancer, the current gold standard for assessing response to treatment involves measuring cancer lesions on computed tomography (CT) imaging. The percentage change in size of specific lesions determines whether patients have had a complete/partial response or progressive...

Descripción completa

Detalles Bibliográficos
Autores principales: Alizzi, Zena, Gogbashian, Andrew, Karteris, Emmanouil, Hall, Marcia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268407/
https://www.ncbi.nlm.nih.gov/pubmed/37322564
http://dx.doi.org/10.1186/s40644-023-00579-2
_version_ 1785059085658357760
author Alizzi, Zena
Gogbashian, Andrew
Karteris, Emmanouil
Hall, Marcia
author_facet Alizzi, Zena
Gogbashian, Andrew
Karteris, Emmanouil
Hall, Marcia
author_sort Alizzi, Zena
collection PubMed
description BACKGROUND: In patients with cancer, the current gold standard for assessing response to treatment involves measuring cancer lesions on computed tomography (CT) imaging. The percentage change in size of specific lesions determines whether patients have had a complete/partial response or progressive disease, according to RECIST criteria. Dual Energy CT (DECT) permits additional measurements of iodine concentration, a surrogate marker of vascularity. Here we explore the role of changes in iodine concentration within cancer tissue on CT scans to assess its suitability for determining treatment response in patients with high grade serous ovarian cancer (HGSOC). METHODS: Suitable RECIST measurable lesions were identified from the CT images of HGSOC patients, taken at 2 different time points (pre and post treatment). Changes in size and iodine concentration were measured for each lesion. PR/SD were classified as responders, PD was classified as non-responder. Radiological responses were correlated with clinical and CA125 outcomes. RESULTS: 62 patients had appropriate imaging for assessment. 22 were excluded as they only had one DECT scan. 32/40 patients assessed (113 lesions) had received treatment for relapsed HGSOC. RECIST and GCIG (Gynaecologic Cancer Inter Group) CA125 criteria / clinical assessment of response for patients was correlated with changes in iodine concentration, before and after treatment. The prediction of median progression free survival was significantly better associated with changes in iodine concentration (p = 0.0001) and GCIG Ca125 / clinical assessment (p = 0.0028) in comparison to RECIST criteria (p = 0.43). CONCLUSION: Changes in iodine concentration from dual energy CT imaging may be more suitable than RECIST in assessing response to treatment in patients with HGSOC. TRIAL REGISTRATION: CICATRIx IRAS number 198179, 14 Dec 2015, https://www.myresearchproject.org.uk/. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-023-00579-2.
format Online
Article
Text
id pubmed-10268407
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102684072023-06-15 Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study Alizzi, Zena Gogbashian, Andrew Karteris, Emmanouil Hall, Marcia Cancer Imaging Research Article BACKGROUND: In patients with cancer, the current gold standard for assessing response to treatment involves measuring cancer lesions on computed tomography (CT) imaging. The percentage change in size of specific lesions determines whether patients have had a complete/partial response or progressive disease, according to RECIST criteria. Dual Energy CT (DECT) permits additional measurements of iodine concentration, a surrogate marker of vascularity. Here we explore the role of changes in iodine concentration within cancer tissue on CT scans to assess its suitability for determining treatment response in patients with high grade serous ovarian cancer (HGSOC). METHODS: Suitable RECIST measurable lesions were identified from the CT images of HGSOC patients, taken at 2 different time points (pre and post treatment). Changes in size and iodine concentration were measured for each lesion. PR/SD were classified as responders, PD was classified as non-responder. Radiological responses were correlated with clinical and CA125 outcomes. RESULTS: 62 patients had appropriate imaging for assessment. 22 were excluded as they only had one DECT scan. 32/40 patients assessed (113 lesions) had received treatment for relapsed HGSOC. RECIST and GCIG (Gynaecologic Cancer Inter Group) CA125 criteria / clinical assessment of response for patients was correlated with changes in iodine concentration, before and after treatment. The prediction of median progression free survival was significantly better associated with changes in iodine concentration (p = 0.0001) and GCIG Ca125 / clinical assessment (p = 0.0028) in comparison to RECIST criteria (p = 0.43). CONCLUSION: Changes in iodine concentration from dual energy CT imaging may be more suitable than RECIST in assessing response to treatment in patients with HGSOC. TRIAL REGISTRATION: CICATRIx IRAS number 198179, 14 Dec 2015, https://www.myresearchproject.org.uk/. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-023-00579-2. BioMed Central 2023-06-15 /pmc/articles/PMC10268407/ /pubmed/37322564 http://dx.doi.org/10.1186/s40644-023-00579-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Alizzi, Zena
Gogbashian, Andrew
Karteris, Emmanouil
Hall, Marcia
Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study
title Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study
title_full Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study
title_fullStr Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study
title_full_unstemmed Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study
title_short Development of a dual energy CT based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study
title_sort development of a dual energy ct based model to assess response to treatment in patients with high grade serous ovarian cancer: a pilot cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268407/
https://www.ncbi.nlm.nih.gov/pubmed/37322564
http://dx.doi.org/10.1186/s40644-023-00579-2
work_keys_str_mv AT alizzizena developmentofadualenergyctbasedmodeltoassessresponsetotreatmentinpatientswithhighgradeserousovariancancerapilotcohortstudy
AT gogbashianandrew developmentofadualenergyctbasedmodeltoassessresponsetotreatmentinpatientswithhighgradeserousovariancancerapilotcohortstudy
AT karterisemmanouil developmentofadualenergyctbasedmodeltoassessresponsetotreatmentinpatientswithhighgradeserousovariancancerapilotcohortstudy
AT hallmarcia developmentofadualenergyctbasedmodeltoassessresponsetotreatmentinpatientswithhighgradeserousovariancancerapilotcohortstudy